行情

AGIO

AGIO

Agios制药
NASDAQ

实时行情|Nasdaq Last Sale

47.58
+0.25
+0.53%
交易中 14:58 03/05 EST
开盘
47.00
昨收
47.33
最高
48.85
最低
45.14
成交量
96.68万
成交额
--
52周最高
58.93
52周最低
27.77
市值
33.12亿
市盈率(TTM)
-10.0380
分时
5日
1月
3月
1年
5年
BioCryst,Editas,Groupon,Sunrun,Twitter和更多周一下午的分析师电话
247WallSt.com · 4天前
Agios为先前治疗过IDH1突变型胆管癌的患者的TIBSOVO向FDA提交补充新药申请
CAMBRIDGE, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and genetically defined diseases, today announced that it has
Benzinga · 4天前
摩根大通将Agios Pharmaceuticals评级下调为中性,宣布目标价为54美元
JP Morgan analyst Anupam Rama downgrades Agios Pharmaceuticals (NASDAQ:AGIO) from Overweight to Neutral and announces $54 price target.
Benzinga · 4天前
Benzinga的最高评级升级,降级2021年2月26日
Upgrades Morgan Stanley upgraded the previous rating for Wayfair Inc (NYSE:W) from Underweight to Equal-Weight. Wayfair earned $1.24 in the fourth quarter, compared to $2.80 in the year-ago quarter. The current stock performance of Wayfair shows a 52-week-...
Benzinga · 02/26 15:04
Oppenheimer维持对Agios Pharma(AGIO)的评级
In a report released today, Mark Breidenbach from Oppenheimer maintained a Hold rating on Agios Pharma (AGIO). The company's shares closed last Thursday
SmarterAnalyst · 02/25 21:25
10-K:AGIOS PHARMACEUTICALS,INC。
Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations You should read the following discussion and analysis of our...
Edgar Online - (EDG = 10Q, 10K) · 02/25 16:39
8-K:AGIOS PHARMACEUTICALS,INC。
(EDGAR Online via COMTEX) -- false 0001439222 0001439222 2021-02-25 2021-02-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 02/25 16:04
每日生物技术动向:默克去购物,莎瑞达公司的决策日,辉瑞公司,Moderna公布冠状病毒变种的疫苗策略
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 24)
Benzinga · 02/25 13:08
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解AGIO最新的财务预测,通过AGIO每股收益,每股净资产,每股现金流等数据分析Agios制药近期的经营情况,然后做出明智的投资选择。
分析师评级

12位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测
分析师预测AGIO价格均价为64.89,最高价位80.00,最低价为50.00。
EPS
机构持股
总机构数: 337
机构持股: 7,011.28万
持股比例: 100.73%
总股本: 6,960.13万
类型机构数股数
增持
63
504.02万
建仓
72
51.26万
减持
74
694.92万
平仓
0
0
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
+0.50%
制药与医学研究
+0.94%
高管信息
Chairman/Director
David Schenkein
Chief Executive Officer/Director
Jacqualyn Fouse
Chief Financial Officer
Jonathan Biller
Senior Vice President/General Manager
Orlando Oliveira
Chief Scientific Officer
Bruce Car
Other
Christopher Bowden
Other
Darrin Miles
Director
David Scadden
Independent Director
Paul Clancy
Independent Director
Ian Clark
Independent Director
Kaye Foster
Independent Director
Maykin Ho
Independent Director
Kaye Foster-Cheek
Independent Director
John Maraganore
暂无数据
AGIO 简况
Agios Pharmaceuticals, Inc.是一家生物制药公司。该公司探索及开发用于治疗癌症及罕见遗传病(罕见遗传代谢疾病)的口服小分子药物。癌症治疗候选产品包括AG-221及AG-120以及AG-881。AG-221及AG-120分别靶向突变型异柠檬酸脱氢酶2及异柠檬酸脱氢酶1(即IDH2及IDH1)。AG-881同时靶向突变型IDH1及突变型IDH2。罕见遗传病计划的主要候选产品AG-348靶向R型丙酮酸激酶。该产品是丙酮酸激酶缺乏症的治疗药物。AG-221是用于治疗癌症的口服选择性突变型IDH2蛋白抑制剂。AG-120是用于治疗癌症的口服选择性突变型IDH1蛋白抑制剂。AG-881是口服的、可穿透脑屏障的选择性泛突变IDH抑制剂。

微牛提供Agios Pharmaceuticals Inc(NASDAQ-AGIO)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的AGIO股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易AGIO股票基本功能。